Figure 21.

RAD52, SL interactions with PARP inhibitors. This figure shows classic SL with PARP inhibition in BRCA2 deficient-cancer cells. These are prone to acquired mutation. The implementation of RAD52 in combination with PARPi has no effect in BRCA2 proficient healthy cells; however, in BRCA2-deficient cancer cells, small-molecule-induced synthetic lethality occurs. Adapted from Cancers, 2019, Vol. 11, Issue (10), , Monika Toma, Katherine Sullivan-Reed, Tomasz Śliwiński, Tomasz Skorski, RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies ,¹⁶² Page 1569, with use of the Attribution 4.0 International (CC BY 4.0) open access license.